Tesamorelin Research Peptide (RUO)

What is Tesamorelin?

Tesamorelin is a stabilised analogue of human growth-hormone-releasing hormone (GHRH), built on the full 44-amino-acid GRF(1-44) sequence and modified at the N-terminus with a trans-3-hexenoyl (hexenoic acid) group. This lipophilic modification confers greater resistance to enzymatic degradation, including by dipeptidyl peptidase-4 (DPP-4), than endogenous GHRH. Mechanistically, tesamorelin acts on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone.

As an active pharmaceutical ingredient, tesamorelin (CAS 218949-48-5, molecular formula C221H366N72O67S, ~5135.86 g/mol) is typically presented as a lyophilised powder. It is approved by the US FDA (since 2010) for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy.

How Tesamorelin Is Produced & Characterised

Tesamorelin is a long, synthetically demanding 44-mer peptide: the extended chain length, the N-terminal hexenoyl acylation and several difficult coupling regions all create opportunities for deletion sequences, diastereomers and incomplete modification. For this peptide class, production is typically carried out by Fmoc solid-phase peptide synthesis (SPPS) with controlled N-terminal acylation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns that isolate the target sequence from closely related impurities.

The purified peptide is generally lyophilised to a stable, uniform powder and released against a defined specification for batch-to-batch consistency. Characterisation usually combines UPLC/HPLC for purity, LC-MS for sequence and impurity profiling, and tests for water content, counter-ion (acetate) content, residual solvents and peptide content. This reflects the general industry and analytical approach for stabilised GHRH-class peptides.

Regulatory & Documentation Context

Tesamorelin is an approved active ingredient: the US FDA cleared it in 2010 for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy. For regulated finished products, the API is generally supported by CMC documentation such as US-DMF Type II dossiers and CTD Module 3 sections, analytical validation packages to ICH Q2(R1), and stability data. These are the standard filing materials referenced in IND/NDA/ANDA submissions.

Manufacturing for regulated markets is typically built around pre-approval-inspection (PAI) readiness aligned to FDA, EMA and PMDA expectations. Research-grade tesamorelin supplied for laboratory use is not the approved medicinal product.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Tesamorelin to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Tesamorelin in their country.